Mereo BioPharma Group plc (0A9G.L)

3,1550 +0,0050 (+0,16%) Alla chiusura: 04:58PM BST

Mereo BioPharma Group plc

One Cavendish Place
4th Floor
London W1G 0QF
United Kingdom
44 33 3023 7300
https://www.mereobiopharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 33

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Denise Vera Scots-Knight Ph.D.	Co-Founder, CEO & Executive Director	890,56k	N/D	1959
Mr. Charles Edward Sermon	Co-Founder, General Counsel, Business Development & Company Secretary	625,79k	N/D	1969
Dr. John P. Richard M.B.A.	Co-Founder & Chief Business Officer	N/D	N/D	1957
Dr. John A. Lewicki Ph.D.	Chief Scientific Officer	N/D	N/D	1952
Dr. Jackie Parkin	Senior VP & Therapeutic Head	N/D	N/D	1958
Ms. Alexandra Hughes-Wilson	Chief of Patient Access & Commercial Planning	N/D	N/D	1971
Dr. Suba Krishnan	Senior Vice President of Clinical Development	N/D	N/D	1965
Mr. Bo Kara	Senior VP and Head of Pharmaceutical Development & CMC	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Mereo BioPharma Group plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.